2,800 Shares in Illumina, Inc. $ILMN Acquired by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,800 shares of the life sciences company’s stock, valued at approximately $492,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ILMN. BlackRock Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at $3,374,423,000. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Illumina during the 2nd quarter worth about $293,846,000. Invesco Ltd. raised its holdings in Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after buying an additional 1,352,731 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,416,384 shares of company stock worth $256,164,151 over the last 90 days. Company insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Guggenheim upped their price objective on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Finally, Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $188.40.

Illumina Stock Performance

NASDAQ ILMN opened at $213.24 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a market cap of $32.20 billion, a P/E ratio of 39.78, a P/E/G ratio of 2.89 and a beta of 1.45. The stock has a 50-day moving average of $186.84 and a two-hundred day moving average of $151.97. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $220.32.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the company earned $1.19 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.